DR6產(chǎn)品信息
英文名稱:Tumor necrosis factor receptor superfamily member 21
中文名稱:腫瘤壞死因子受體超家族成員21
靶點(diǎn)別稱:TNFRSF21,DR6,CD358,BM-018
物種:Human
標(biāo)簽:Fc Tag
屬性:Protein
標(biāo)記:Unconjugated
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human DR6, Fc Tag (TN1-H5252) is expressed from human 293 cells (HEK293). It contains AA Gln 42 - Leu 350 (Accession # AAH17730).
Predicted N-terminus: Gln 42
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 60.2 kDa. The protein migrates as 80-95kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>90% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 150 mM NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
腫瘤壞死因子受體超家族成員21(TNFRSF21)也稱為死亡受體6(DR6),是TNF受體超家族的成員。TNFRSF21包含一個(gè)死亡結(jié)構(gòu)域和四個(gè)TNFR-Cys重復(fù)序列。TNFRSF21/DR6已被證明可以激活NF-κB和MAPK8/JNK,并誘導(dǎo)細(xì)胞凋亡。通過其死亡結(jié)構(gòu)域,該受體與TRADD蛋白相互作用,TRADD蛋白被認(rèn)為是介導(dǎo)TNF受體信號(hào)轉(zhuǎn)導(dǎo)的接頭。
關(guān)鍵字: TNFRSF21;DR6蛋白;DR6重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國(guó)生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。